Drug × Cancer matrix

Drugs that target a gene either directly (oncogene) or via a synthetic-lethal partner (SLP) of a mutated tumour suppressor (TSG). Cell colour shows the strongest known status of that drug for that cancer subtype: approved clinical trial repositionable (potential reuse, no evidence yet) or blank.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Relationship
Show
Clear
Showing 92 of 92 drug-target rows in SSL view, for TSG = KMT2D.
Drug TSG SLP (drug target) GBM LUAD SCLC LUSC OAC OSCC PDAC #
olaparib KMT2D PARP1 1
trastuzumab emtansine KMT2D ERBB2 7
tucatinib KMT2D ERBB2 7
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KMT2D SMO 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib KMT2D ERBB2 3
afatinib KMT2D ERBB2 3
mrtx849, pembrolizumab, cetuximab, afatinib KMT2D ERBB2 3
lapatinib KMT2D ERBB2 7
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel KMT2D ERBB2 2
alvocidib, paclitaxel KMT2D CDK9 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab KMT2D ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib KMT2D ERBB2 2
pembrolizumab, sonidegib KMT2D SMO 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies KMT2D ERBB2 2
trastuzumab KMT2D ERBB2 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy KMT2D ERBB2 2
trastuzumab, tipifarnib KMT2D ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks KMT2D ERBB2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy KMT2D ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging KMT2D ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib KMT2D ERBB2 1
afatinib, docetaxel, radiation therapy KMT2D ERBB2 1
afatinib, gefitinib KMT2D ERBB2 1
afatinib, irinotecan KMT2D ERBB2 1
alvocidib, docetaxel KMT2D CDK9 1
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis KMT2D CDK9 1
apg101, alectinib, idasanutlin, atezolizumab, vismodegib, temsirolimus, palbociclib KMT2D SMO 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab KMT2D ERBB2 1
biopsy, biospecimen collection, echocardiography, radionuclide imaging, vismodegib KMT2D SMO 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab KMT2D ERBB2 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab KMT2D ERBB2 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin KMT2D TP53 1
cetuximab, trastuzumab KMT2D ERBB2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy KMT2D ERBB2 1
db-1310, trastuzumab, osimertinib KMT2D ERBB2 1
diagnostic laboratory biomarker analysis, erlotinib hydrochloride, gemcitabine hydrochloride, vismodegib KMT2D SMO 1
disitamab vedotin, tucatinib KMT2D ERBB2 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab KMT2D ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab KMT2D ERBB2 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) KMT2D CHEK2 1
enzastaurin, bevacizumab, enzyme-inducing antiepileptic drugs (eiaed), non-enzyme inducing antiepileptic drugs (neiaed) KMT2D CHEK1 1
enzastaurin, lomustine KMT2D CHEK2 1
enzastaurin, lomustine KMT2D CHEK1 1
enzastaurin, temozolomide, radiation therapy KMT2D CHEK2 1
enzastaurin, temozolomide, radiation therapy KMT2D CHEK1 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel KMT2D ERBB2 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig KMT2D ERBB2 1
gemcitabine hydrochloride, hydrocortisone/placebo, vismodegib KMT2D SMO 1
gemcitabine, ribociclib, sonidegib, trametinib, filgrastim KMT2D SMO 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery KMT2D ERBB2 1
lapatinib, chemoradiation, placebo KMT2D ERBB2 1
lapatinib, placebo KMT2D ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin KMT2D ERBB2 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab KMT2D ERBB2 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab KMT2D ERBB2 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab KMT2D ERBB2 1
palbociclib, afatinib KMT2D ERBB2 1
pazopanib, lapatinib KMT2D ERBB2 1
pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab KMT2D ERBB2 1
pembrolizumab, trastuzumab, oxaliplatin, capecitabine KMT2D ERBB2 1
tesevatinib KMT2D ERBB2 1
tirelizumab, trastuzumab, docetaxel, s1, oxaliplatin KMT2D ERBB2 1
trastuzumab, cyclophosphamide, doxorubicin hydrochloride, lapatinib ditosylate, paclitaxel, gene expression analysis, reverse transcriptase-polymerase chain reaction, fluorophotometry, laboratory biomarker analysis, mass spectrometry, adjuvant therapy, quality-of-life assessment KMT2D ERBB2 1
trastuzumab, pertuzumab, paclitaxel, carboplatin KMT2D ERBB2 1
trilaciclib KMT2D CDK9 1
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab KMT2D ERBB2 1
tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo KMT2D ERBB2 1
vismodegib, sirolimus, positron emission tomography, computed tomography, pharmacological study, laboratory biomarker analysis, fludeoxyglucose f 18 KMT2D SMO 1
vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study KMT2D SMO 1
zanidatamab, tislelizumab, trastuzumab, capecitabine, oxaliplatin, cisplatin, 5-fluorouracil KMT2D ERBB2 1
zongertinib, trastuzumab deruxtecan, trastuzumab emtansine KMT2D ERBB2 1
afatinib dimaleate KMT2D ERBB2 7
glasdegib KMT2D SMO 7
glasdegib maleate KMT2D SMO 7
lanreotide KMT2D ERBB2 7
lanreotide acetate KMT2D ERBB2 7
lapatinib ditosylate KMT2D ERBB2 7
neratinib KMT2D ERBB2 7
neratinib maleate KMT2D ERBB2 7
niraparib KMT2D PARP1 7
niraparib tosylate KMT2D PARP1 7
pertuzumab KMT2D ERBB2 7
rucaparib KMT2D PARP1 7
rucaparib camsylate KMT2D PARP1 7
sonidegib KMT2D SMO 7
sonidegib phosphate KMT2D SMO 7
talazoparib KMT2D PARP1 7
talazoparib tosylate KMT2D PARP1 7
vandetanib KMT2D ERBB2 7
vismodegib KMT2D SMO 7
trastuzumab deruxtecan KMT2D ERBB2 4
dacomitinib KMT2D ERBB2 2
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable candidates from cansar.ai — these are potential drug-cancer reuse candidates, not evidence of efficacy.